Baseline sleep duration and quality significantly influence weight loss outcomes and physical activity increases in a 12-month behavioral program.

Guidelines suggest CBT-I plus medication is more effective than medication alone for adults with chronic insomnia disorder.

Ozempic tablets will launch nationwide on May 4, 2026, offering a reformulated and smaller pill for type 2 diabetes and cardiovascular risk management.

Long-term adherence to Mediterranean and MIND diets is associated with a reduced risk for dementia and slower cognitive ...

Higher vitamin D levels in early midlife are associated with lower tau deposition in later midlife among adults without dementia.

The FDA has approved Auvelity (dextromethorphan HBr/bupropion HCl) for Alzheimer disease agitation, providing a non-antipsychotic option based on ADVANCE-1 and ACCORD-2 data.

There is a greater risk for the development of behavioral problems among children born with congenital heart disease.

The FDA is testing real-time clinical trial reporting in an effort to speed up the drug review and approval process.

Cognitive function may deteriorate preceding cardiovascular events among older adults, highlighting the value of early cognitive screening.

What were the most significant improvements seen in the Myasthenia Gravis-Activities of Daily Living and Quantitative ...

Tavapadon significantly improves motor function and activities of daily living in adults with early Parkinson disease compared with placebo.

Recent data show high interest and use of spiritual practices and manual therapies among older individuals, particularly those with depression.